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Abstract
Objective To undertake a process evaluation of pharmacists’ recommendations
arising in the context of a complex IT-enabled pharmacist-delivered randomised
controlled trial (PINCER trial) to reduce the risk of hazardous medicines manage-
ment in general practices.
Methods PINCER pharmacists manually recorded patients’ demographics, details
of interventions recommended, actions undertaken by practice staff and time taken
to manage individual cases of hazardous medicines management. Data were coded,
double-entered into SPSS version 15 and then summarised using percentages for
categorical data (with 95% confidence interval (CI)) and, as appropriate, means
( standard deviation) or medians (interquartile range) for continuous data.
Key findings Pharmacists spent a median of 20 min (interquartile range 10, 30)
reviewing medical records, recommending interventions and completing actions in
each case of hazardous medicines management. Pharmacists judged 72% (95% CI
70, 74; 1463/2026) of cases of hazardous medicines management to be clinically rel-
evant. Pharmacists recommended 2105 interventions in 74% (95% CI 73, 76; 1516/
2038) of cases and 1685 actions were taken in 61% (95% CI 59, 63; 1246/2038) of
cases; 66% (95% CI 64, 68; 1383/2105) of interventions recommended by pharma-
cists were completed and 5% (95% CI 4, 6; 104/2105) of recommendations were
accepted by general practitioners (GPs), but not completed at the end of the pharma-
cists’ placement; the remaining recommendations were rejected or considered not
relevant by GPs.
Conclusions The outcome measures were used to target pharmacist activity in
general practice towards patients at risk from hazardous medicines management.
Recommendations from trained PINCER pharmacists were found to be broadly
acceptable to GPs and led to ameliorative action in the majority of cases. It seems
likely that the approach used by the PINCER pharmacists could be employed by
other practice pharmacists following appropriate training.
Introduction
An estimated 16.5% of patients in primary (ambulatory)
care are estimated to experience preventable adverse drug
events.[1] Preventable adverse drug events are associated with
hazardous medicines management and their incidence can
therefore potentially be reduced by improving the safety of
prescribing and monitoring in primary care. This patient
safety role of pharmacists in UK hospital settings is well
established with pharmacists’ interventions being widely
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accepted as improving patient care.[2–4] However, the role of
pharmacists in improving patient safety in general practice is
in contrast far less well established with conflicting evidence
from studies. Our systematic review and meta-analysis found
weak evidence that pharmacist interventions in primary care
could reduce hospital admissions.[5] Subsequent studies,
however, found that pharmacist-led medication reviews have
either no effect on hospital admissions[6] or increase hospital
admissions.[7]
The PINCER trial was a cluster randomised controlled trial
which demonstrated that pharmacists working in general
(family) practices substantially reduced the frequency of
clinically important medication errors; this reduction is
highly likely to translate into fewer preventable adverse drug
events in primary care. Therefore the PINCER trial shows
that pharmacists working in a primary care setting can
provide a cost-effective intervention that should reduce
patient harm.[8,9] The detailed trial methods and main find-
ings have been reported elsewhere.[8–10] In summary, the inter-
vention involved identifying patients potentially at risk of
harm from hazardous medicines management using Quest
Browser software (The Computer Room, Nottingham, UK)
to search general practice electronic patient records. The
Quest Browser searches were based on 10 outcome measures
relating to contraindicated prescribing, inadequate monitor-
ing and inappropriate dosing of medication (see Box 1).
Seventy-two general practices were recruited from an 80 km
radius around Manchester and Nottingham in the UK and
were randomised to receive either simple feedback (36 prac-
tices) or pharmacist intervention (36 practices).
Practices receiving simple feedback were given paper
copies of the Quest Browser search results and evidence-
based summaries to support each outcome measure. These
practices did not receive support from a pharmacist as part of
the trial. In the pharmacist-intervention arm, six pharmacists
with varied backgrounds[11] worked for 2 days per week for up
to 12 weeks (i.e. one pharmacist per practice). At the start of
their work in each practice the pharmacists met with
members of the practice team to discuss the Quest Browser-
generated feedback on patients with potentially hazard-
ous medicines management. Where possible this meeting
included all general practitioners (GPs) from the practice, at
least one nurse, one receptionist and the practice manager.
Before the meeting, practice staff were given a summary
of the Quest Browser-generated feedback and copies of
evidence-based summaries which supported each outcome
measure. During the meeting, pharmacists used the princi-
ples of educational outreach[12–14] to communicate important
messages about why the medicines management was hazard-
ous while also taking account of human error theory[15] and
using root-cause analysis techniques, as appropriate.[16] Fol-
lowing this meeting the pharmacists worked closely with a
designated liaison person in each practice to help improve
systems of work to prevent future medicines management
problems. After 6–8 weeks pharmacists held follow-up meet-
ings with practice staff to review progress. To resolve existing
Box 1 Outcome measures (OM) used to identify patients at risk from hazardous medicines management
Contraindicated prescribing
OM1 Patients with a history of peptic ulcer who have been prescribed a non-selective non-steroidal anti-inflammatory
drug without co-prescription of a proton-pump inhibitor
OM 2 Patients with asthma who had been prescribed a b-blocker
OM 4 Women with a past medical history of venous or arterial thrombosis who had been prescribed the combined oral
contraceptive pill
Inadequate monitoring
OM 3 Patients aged 75 years and older who have been prescribed an angiotensin-converting enzyme inhibitor or a loop
diuretic long-term who had not had a computer-recorded check of their renal function and electrolytes in the pre-
vious 15 months
OM 5 Patients receiving methotrexate for at least 3 months who had not had a full blood count recorded, or liver function
test, in the previous 3 months
OM 6 Patients receiving warfarin for at least 3 months who had not had a recorded check of their international normalised
ratio in the previous 12 weeks
OM 7 Patients receiving lithium for at least 3 months who had not had a recorded check of their lithium concentrations in
the previous 3 months
OM 8 Patients receiving amiodarone for at least 6 months who had not had a thyroid function test in the previous 6 months
Dosing problems
OM 9 Patients receiving prescriptions of methotrexate without instructions that the drug should be taken every week
OM 10 Patients receiving prescriptions of amiodarone for at least 1 month who are receiving a dose of more than 200 mg per
day
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medicines management problems pharmacists also reviewed
each case of potentially hazardous medicines management
identified by the Quest Browser searches. Pharmacists used
their clinical expertise to determine whether the patients
identified were at clinical risk of harm, and recommended
interventions to reduce the risk of harm to patients. Interven-
tions were communicated to GPs using a handwritten form
(the case-specific record; see Box 2). Where interventions
were accepted by GPs, pharmacists and other members of the
practice staff implemented the changes. Where interventions
were not accepted GPs either continued current care or rec-
ommended their own changes to patients’ treatments.
This paper aims to describe the patient-specific inter-
ventions recommended by pharmacists implementing the
PINCER trial intervention, how much time pharmacists
spent on these interventions and the percentage of interven-
tions accepted by GPs. This will help pharmacists and com-
missioners of services understand how the patient-specific
work of pharmacists in primary care can help reduce the risk
of preventable adverse drug events.
Methods
Ethical approval for the PINCER trial was obtained from the
Nottingham 2 Research Ethics Committee (reference number
05/Q2404/26) on 15 March 2005.
Data collection
Six PINCER pharmacists manually completed two record
forms: a summary record (Form 1) and a case-specific record
(Form 2) (see Box 2). These forms recorded the pharmacists’
activity for each case that they reviewed while working in
intervention practices. Additionally, pharmacists were also
asked to record on Form 1 whether they judged a patient to
have been identified by the Quest Browser searches (i)
because they were at clinical risk of harm, (ii) because there
was an error in the medical record (coding error), (iii)
because information was available in the medical records but
not coded or (iv) for another reason (pharmacists were not
asked to specify the other reason).
Data entry
Data from the summary record (Form 1) were entered into
SPSS version 15[17] and data entry was independently double-
checked for accuracy. Discrepancies were noted and corrected
by referring to the summary record in 553 (27%) cases.
Where interventions and actions completed were coded as
‘other action’, case-specific records (Form 2) were reviewed
(597/2038; 29%) and the actions recoded as one of an addi-
tional 53 types of intervention or action completed. These
data were single-entered into SPSS version 15.[17] Data were
validated by checking that actions recommended or com-
pleted were appropriately coded for each outcome measure
(discrepancies were noted in 15 (2%) entries and corrected by
referring back to the case-specific record). Duplicate data
were noted for eight cases and these duplicate entries were
removed.
Interventions recommended by pharmacists were com-
pared with actions completed within the practice for each
case and coded to indicate whether interventions had been
accepted, rejected, were still to be completed, an alternative or
additional action had been taken, or the outcome was
unknown. Data entry was double-checked and discrepancies
noted and corrected in 74 (4%) cases.
Box 2 Forms completed by pharmacists when reviewing individual patient cases
Form 1: the ‘summary record recorded the following data:
• patient ID (numerical code),
• patient age and gender,
• GP’s initials,
• outcome measure (numerical code) (see Box 1),
• numerical code describing pharmacist’s judgement of why a patient was identified by the Quest Browser search (patient at
risk of harm, coding error, information available in medical records but not coded, other reason),
• numerical code describing pharmacist’s interventions and actions completed,
• pharmacist’s estimate of the time they spent reviewing each case and implementing actions,
• pharmacist’s initials and date record completed.
Form 2: the case-specific record recorded the following data:
• detailed notes describing each patient’s medication problem,
• description of interventions which the pharmacist recommended,
• GP’s comments about the recommended interventions (not completed in all cases),
• description of actions taken to resolve the medication problem,
• summary of how the patient was contacted.
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Data analysis
Data were summarised using percentages for categorical data
(95% confidence interval (CI)), and means ( standard
deviation) for normally distributed data and medians (inter-
quartile range) for non-normally distributed data.
Results
Patient characteristics
A total of 1946 patients (from 228 748 patients registered in
36 practices) were identified as at risk from 2038 cases of
potentially hazardous medicines management. Ninety-five
per cent (95% CI 95, 95; 1854/1946) of patients were identi-
fied by one outcome measure, 5% (95% CI 4, 6; 92/1946)
were identified by two outcome measures and none were
identified by more than two outcome measures. Fifty-nine
per cent (95% CI 57, 61; 1149/1946) of patients were female
and the mean age was 68.2 years (standard deviation16.3
years).
Pharmacists’ judgements of why patients
were identified by Quest Browser searches
Pharmacists judged that 1463/2026 (72%; 95% CI 70, 74)
cases were clinically at risk (data were missing for 12 cases
which pharmacists did not have time to review). The reasons
why cases identified by the Quest Browser searches were
judged not to be at clinical risk were: (i) because the necessary
information was available, but not coded on the computer
(43/2026; 2%; 95% CI 2, 3) (for example, blood results were
received in letters and scanned into the computer, but not
coded into the results section of a patient’s electronic record),
(ii) because the information had been coded incorrectly
on the computer (66/2026; 3%; 95% CI 3, 4) and (iii) for
other ‘unspecified’ reasons (461/2026; 23%; 95% CI 16, 30)
(Table 1).
The percentage of at-risk cases varied markedly between
outcome measures (Table 1), with 90% or more cases consid-
ered at risk for outcome measures 1, 3 and 8, whereas fewer
than 40% of cases were considered to be at risk for outcome
measures 6 and 9 (see Table 1).
Estimated time taken for pharmacists to
review cases, recommend interventions
and complete agreed actions
Pharmacists estimated that they took a median of 20 min
(interquartile range 10, 30) to review each case, recommend
interventions and complete agreed actions. The median
estimated time taken varied between outcome measures from
10 min (to manage cases associated with oral contraceptive
pills and arterial or venous thrombosis and inappropriate
dosing of methotrexate) to 30 min (for cases associated with
asthma and b-blockers) (Table 1). The total estimated time
spent assessing cases, making recommendations and com-
pleting agreed actions was 732.7 h (97.7 working days);
equivalent to 2.7 working days per practice (based on a stand-
ard NHS pharmacist contract of 7.5 h per day). This varied
from a median of 1.2 days (range 0.5–1.6 days) for small prac-
tices (list size <2500 patients), a median of 1.3 days (range
0.6–3.2 days) for medium practices (list size 2500–6000
patients) and a median of 3.3 days (range 1.2–8.2 days) for
large practices (list size >6000 patients).
Table 1 Number (%) of cases judged to be at clinical risk by outcome measure
Outcome measure
Number (%)
cases identified
(n = 2038)
Number cases at clinical
risk (% of cases identified
for each outcome measure)
Median (interquartile range)
time taken for a pharmacist
to manage each case (min)
Total pharmacist
intervention time (h)
1 Non-steroidal anti-inflammatory drug and
peptic ulcer
89 (5) 80 (90) 20 (15, 30) 38.5
2 Asthma and b-blocker 535 (26) 433 (81) 30 (15, 45) 273.2
3 Angiotensin-converting enzyme
inhibitor/diuretic and laboratory test
561 (28) 526 (94) 15 (10, 30) 198.6
4 Arterial or venous thrombosis and
combined oral contraceptive
5 (0) 4 (80) 10 (10, 40) 1.8
5 Methotrexate and full blood count or liver
function test
181 (9) 105 (58) 17.5 (10, 25) 58.6
6 Warfarin and INR 213 (11) 50 (24) 15 (10, 20) 28.5
7 Lithium and lithium levels 99 (5) 74 (75) 15 (10, 30) 33.6
8 Amiodarone and thyroid-function tests 118 (6) 112 (95) 20 (15, 30) 50.4
9 Methotrexate and weekly dosage 228 (11) 73 (32) 10 (5, 15) 45.7
10 Amiodarone and daily dosage 9 (0) 6 (67) 20 (10, 40) 3.8
All cases 2038 (100) 1463 (72) 20 (10, 30) 732.7
INR, International Normalised Ratio.
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Number of interventions recommended by
the pharmacists
Pharmacists recommended 2105 interventions to help
resolve medication problems in 1516/2038 cases (74%; 95%
CI 73, 76) identified by the Quest Browser searches. In 1073
cases (53%; 95% CI 50, 55) one recommendation was made,
in 335 cases (16%; 95% CI 16, 17) two recommendations
were made, in 70 cases (3%; 95% CI 3, 4) three recommenda-
tions were made and in 38 cases (2%; 95% CI 1, 2) four rec-
ommendations were made. In those judged to be at risk of
clinical harm, overall 1782 interventions were recommended
in 1282/1463 cases (88%; 95% CI 86, 89).
Actions taken to reduce the risk to patients
from hazardous medicines management
Overall, 1685 actions were taken in 1246/2038 cases (61%;
95% CI 59, 63) identified by the Quest Browser searches.
Some 1383/2105 (66%; 95% CI 64, 68) of the interventions
recommended by pharmacists were completed. Where phar-
macists considered cases to be at risk of clinical harm 1420
actions were undertaken in 1066/1463 cases (73%; 95% CI
71, 75). In these at-risk cases 1165/1782 interventions (65%;
95% CI 63, 68) recommended by pharmacists were com-
pleted. In addition to the interventions recommended by
pharmacists, GPs took additional or alternative actions. Also,
some interventions were accepted by GPs, but the pharma-
cists documented that they had not been completed when
the pharmacist finished working in the practice. For
example, a GP agreed that a patient’s b-blocker prescription
should be reviewed, but this review had not happened when
the pharmacist left the practice. In other cases it was
unknown whether the intervention had been accepted
because the pharmacist had not documented on the
summary record that the intervention was completed or
rejected (Table 2).
Interventions recommended for
contraindicated prescribing problems
Pharmacists recommended 804 interventions in 515/629
cases (82%; 95% CI 79, 85) of contraindicated prescribing
associated with b-blockers, non-steroidal anti-inflammatory
drugs (NSAIDs) and combined oral contraceptives. Actions
were taken to help resolve problems with contraindicated
prescribing in 370/629 cases (59%; 95% CI 55, 63). Ninety
per cent of pharmacists’ recommendations to update elec-
tronic patient records with properly coded test results or
diagnoses were accepted; half of pharmacists’ recommenda-
tions to review contraindicated medications or monitor
patients more closely were accepted and a third of recom-
mendations to prescribe protective medication or counsel
patients were accepted. Adding screen messages to the elec-
tronic patient records to remind GPs to undertake these rec-
ommendations were completed in more cases than were
recommended by pharmacists (see Table 3) because GPs
suggested adding these reminders after reading pharmacists’
interventions.
Interventions recommended for
monitoring problems
Pharmacists recommended 1171 interventions in 878/1172
cases (75%; 95% CI 73, 77) of inadequate monitoring in
patients taking diuretics, angiotensin-converting enzyme
inhibitors, lithium, amiodarone, warfarin and methotrexate.
Some 1073 actions were taken to help resolve problems with
inadequate monitoring in 796/1172 cases (68%; 95% CI 65,
71). Pharmacists’ recommendations to enter existing test
results, arrange appointments for patients to have blood tests,
contact secondary care to obtain existing test results and ask
specialist clinics to amend the general practice code used for
lab-linking to ensure that test results are automatically
received were accepted in 89% of cases (885/997; 95% CI 87,
Table 2 Number of interventions recommended by PINCER pharmacists, and subsequent actions taken in response
Number of interventions (% of
interventions recommended)
All cases
Cases considered
to be at clinical risk
Interventions recommended by pharmacists 2105 1782
Actions taken by pharmacists and practice staff 1685 1420
Outcome of interventions recommended by
pharmacists
Completed 1383 (66) 1165 (65)
Rejected by GP or patient 441 (21) 357 (20)
Unknown whether completed or rejected 177 (8) 160 (9)
Accepted by GP, but not completed at end of
placement
104 (5) 99 (6)
GP took an alternative action to that recommended by the pharmacist (% of actions taken) 201 (12) 159 (11)
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91). Recommendations to use searches of computer systems
to highlight patients overdue for monitoring, set up screen
reminders to ensure patients have regular monitoring, and
clarify and record who is responsible for monitoring patients
were completed in more cases than they were recommended
because GPs recommended running these searches after
reading pharmacists’ interventions (see Table 4).
Interventions recommended for
dosing problems
Pharmacists recommended 130 interventions in 123/237
cases (52%; 95% CI 46, 58) of potential dosing problems in
patients taking methotrexate and amiodarone. Eighty-six
actions were taken to help resolve problems with inadequate
monitoring in 80/237 cases (34%; 95% CI 28, 40). Pharma-
cists’ recommendations to alter the quantity or strength of
methotrexate supplied were accepted in all five cases, to
amend dosage instructions of methotrexate or amiodarone
were accepted in 64% of cases (67/104; 95% CI 55, 74) and to
start or increase the dose of folic acid were accepted in 75% of
cases (6/8; 95% CI 45, 101) (see Table 5).
Discussion
Analysis of the pharmacist-recorded data on individual cases
of potentially hazardous medicines management identified
by the Quest Browser searches has shown that pharmacists
judged 72% of cases to be at clinical risk of harm. Pharmacists
recommended interventions to help improve the safety of
medicines management in 74% of cases identified and 66% of
their interventions were accepted by GPs and completed.
Additional or alternative actions to improve the safety of
medicines management were taken by GPs, meaning that
actions were completed in 61% of cases identified by the
Table 3 The interventions recommended, and actions taken, in cases of contraindicated prescribing
Description of interventions recommended by
pharmacists
No (%) of
interventions
(n = 804)
Description of actions taken by
pharmacists and practice staff
No (%) of
actions
(n = 512)
Recommend review contraindicated medication 337 (42) Contraindicated medication reviewed 175 (34)
Review, stop or wean b-blocker, or change to
bisoprolol
279 (35) b-Blocker stopped or weaned off 68 (13)
b-Blocker to be reviewed 36 (7)
b-Blocker changed to bisoprolol 23 (4)
Contact consultant to query b-blocker 19 (2) b-Blocker queried with consultant 15 (3)
Stop NSAID or combined oral contraceptive 39 (5) NSAID or combined oral contraceptive stopped 29 (6)
Other 4 (1)
Recommend monitoring 188 (23) Monitoring need accepted 95 (19)
Recommend asthma monitoring 179 (22) Asthma review booked 68 (13)
Recommend other monitoring (blood pressure or
medication reviews)
9 (1) Other monitoring completed (blood pressure or
medication review)
27 (5)
Recommend amend patient’s medical record 106 (13) Patient’s medical record amended 100 (20)
Correct coding error 66 (8) Correct coding error 69 (13)
Add codes (e.g. blood test result, asthma resolved to
history or diagnosis detail to problem screen)
24 (3) Add codes (e.g. blood test) 14 (3)
Request confirmation of diagnosis 20 (2) Diagnosis confirmed 13 (3)
Recommend add screen messages to medical
record as reminders
59 (7) Screen messages added to medical record 107 (21)
Add screen message advising avoid NSAIDs 25 (3) Screen message added advising avoid NSAIDs 29 (6)
Add screen message reminding to monitor asthma
with b-blocker
23 (3) Screen message added reminding to monitor asthma
with b-blocker
46 (9)
Add other screen messages 11 (1) Other screen messages added 32 (6)
Recommend patient counselling 54 (7) Patient counselling completed 18 (4)
Counsel patient regarding risks of taking medication 54 (7) Patient counselled regarding risks of taking
medication
18 (4)
Recommend review protective medication 33 (4) Protective medication reviewed 12 (2)
Add proton-pump inhibitor 29 (4) Add proton-pump inhibitor 11 (2)
Other 4 (0) Other 1 (0)
Recommend other changes (not directly related
to the indicator)
27 (3) Other changes made (not directly related to the
indicator)
5 (1)
NSAID, non-steroidal anti-inflammatory drug.
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Quest Browser searches. Pharmacists estimated that they
spent a median of 20 min reviewing each case, recommend-
ing interventions and completing actions. Pharmacists rec-
ommended a broad range of interventions to help reduce the
risk of harm to individual patients. Many of these recommen-
dations would have implications for the future management
of these patients and, in some cases, other patients within the
practices.
Strengths and limitations
The PINCER trial was a large cluster randomised controlled
trial which clearly demonstrated the effectiveness of a
pharmacist-led IT-enabled intervention in reducing the risk
to patients from hazardous medicines management. The
strengths and limitations of the trial have been discussed in
detail elsewhere.[8,9,11,18]
Table 4 The interventions recommended, and actions taken, in cases of inadequate monitoring
Description of interventions recommended by
pharmacists
No (%) of
interventions
(n = 1171)
Description of actions taken
by pharmacists and practice staff
No (%) of
actions
(n = 1065)
Getting and recording test results/monitoring 997 (85) Getting and recording test results/monitoring 885 (83)
Arrange blood tests 703 (60) Blood tests arranged 614 (58)
Read code blood test results 148 (13) Blood test results read coded 132 (12)
Obtain blood test results from secondary care or
self-monitoring patient and read code
84 (7) Blood test results obtained from secondary care and
self-monitoring patients and read coded
87 (8)
Contact warfarin clinic and request regular results via
lablink
55 (5) Warfarin clinic changed general practice code to
ensure ‘lab-link’ results received
43 (4)
Other interventions recommended relating to
monitoring
7 (1) Other actions taken related to monitoring 8 (1)
Patient specific reasons why monitoring not
completed
12 (1)*
Recommend ways to identify patients needing
monitoring
150 (13) Actions completed to help identify patients
needing monitoring
160 (15)
Monitor exceptions with search template 55 (5) Monitor exceptions with search template 51 (5)
Review and record monitoring arrangements on
electronic patient record
49 (4) Monitoring arrangements confirmed and
documented on electronic patient record
57 (5)
Screen message to monitor bloods 3-monthly 46 (4) Screen message re: bloods added 52 (5)
Changes to medication recommended
(unrelated to indicator)
17 (1) Changes to medication made (unrelated to the
indicator)
12 (1)
Changes to medication recommended due to
deranged blood test results
7 (1) Medication changes completed due to
deranged blood test results
8 (1)
*Includes nine patients who declined bloods, two patients who could not be contacted and one patient who could not be bled.
Table 5 The interventions recommended, and actions taken, in cases with dosing problems
Description of interventions recommended by
pharmacists
No (%) of
interventions
(n = 130)
Description of actions taken
by pharmacists and practice staff
No (%) of
actions
(n = 86)
Recommend changes to prescription 106 (82) Recommend changes to prescription 69 (80)
Alter dosage instructions for methotrexate or
amiodarone
104 (80) Dosage instructions for methotrexate or amiodarone
altered
67 (78)
Other 2 (2) Other 2 (2)
Other actions (not directly related to the
indicator)
24 (18) Other actions (not directly related to the
indicator)
17 (20)
Recommend prescribe, or increase dose of, folic acid 8 (6) Folic acid prescribed, or dose increased 6 (7)
Other interventions related to monitoring
methotrexate or amiodarone
7 (5) Other actions taken related to monitoring
methotrexate or amiodarone
3 (3)
Recommend change strength of methotrexate
tablets or reduce quantity supplied
5 (4) Methotrexate strength changed or quantity supplied
reduced
5 (6)
Other action (unspecified) 4 (3) Other action (unspecified) 3 (3)
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During their work on the PINCER trial, pharmacists
recorded data on individual cases of potentially hazardous
medicines management. As part of this data recording, phar-
macists judged whether patients identified by the Quest
Browser searches were at risk of clinical harm. These judge-
ments were based on the clinical expertise of one pharmacist
in each case and other healthcare professionals may not agree
with their judgements. Pharmacists did not keep detailed
records of the basis for their judgements; therefore, it is not
possible to further identify their ‘unspecified reasons’ for not
judging patients to be at clinical risk.
Additionally, pharmacists’ recommendations to improve
medicines management were not peer reviewed for appropri-
ateness or missed opportunities to intervene. Therefore, it
is possible that some interventions were rejected by GPs
because they were inappropriate or that opportunities to
improve medicines management were missed.
The data recorded by the pharmacists help us understand
how they approach individual cases of hazardous medicines
management in order to help protect patients from harm.
These data also help us predict which interventions are most
likely to be accepted by general practice staff. These data do
not, however, help us understand why some recommenda-
tions were not accepted.
Pharmacists estimated the time they spent reviewing, rec-
ommending interventions and completing actions for indi-
vidual cases of hazardous medicines management. These
times may under- or over-estimate the actual time spent by
the pharmacists on individual patient cases and do not indi-
cate how long was spent on each specific task. Pharmacists’
estimates of time spent reviewing individual cases indicate
that most time was spent on other duties such as meeting with
practice staff and implementing new systems of working
in the practices; however, pharmacists did not record the
time they spent on these activities. Additionally, these roles
are not detailed in the pharmacist-recorded data and this
limits the usefulness of these data in terms of understanding
the role of the pharmacist in the PINCER trial. However,
additional qualitative data collected as part of the PINCER
trial[18] does provide better understanding of this extended
role.
Usefulness of outcome measures for
identifying patients at clinical risk of harm
Pharmacists judged that three-quarters of cases identified by
Quest Browser searches were at clinical risk of harm, suggest-
ing that such outcome measures are a useful way of targeting
pharmacists’ activity. However, the proportion of patients
considered at clinical risk of harm varied greatly between
outcome measures. Ninety to ninety-five per cent of patients
identified by outcome measures 1, 3 and 8 (relating to con-
traindicated prescribing of NSAIDs and inadequate monitor-
ing with diuretics, angiotensin-converting enzyme inhibitors
and amiodarone) were judged to be at clinical risk. In con-
trast, one-quarter of patients identified by outcome measure
6 (related to inadequate monitoring of warfarin) were judged
to be at clinical risk. However, 54% (114/213) of these were
registered in one practice that had a separate recording
system for patients’ International Normalised Ratios (INRs),
which was not identified by the Quest Browser searches. By
excluding these data, half of patients were considered to be
at clinical risk by the pharmacists. In outcome measure
9 (related to the inappropriate dosing of methotrexate)
the IT-enabled searches were unable to reliably identify
patients without a weekly instruction. This meant that
only 32% of patients identified as having no instruction
to take their methotrexate once weekly were judged to
be at clinical risk. This is an important problem which
needs to be resolved before IT-enabled searches can be
used to identify patients at risk from inappropriate dosing of
medication.
Pharmacists’ interventions
Pharmacists made recommendations to improve medicines
management in 74% of the cases identified and in 88% of
cases where they considered patients to be at clinical risk. This
is consistent with Zermansky et al. where pharmacists recom-
mended interventions for 75% of general practice patients.[19]
In the PINCER trial, 66% of interventions recommended by a
pharmacist were completed, compared to 56% of pharma-
cists’ interventions recommended in the Zermansky et al.
study of medication reviews in a nursing home setting.[20,21]
This suggests that pharmacists’ interventions were broadly
acceptable to the GPs. This finding is supported by a qualita-
tive evaluation of the PINCER intervention, which demon-
strated that the trial intervention had face validity and was
acceptable to GPs and their teams.[18]
In the intervention arm of the PINCER trial one-fifth of
pharmacists’ recommendations were not accepted by GPs
or patients. However, even when pharmacists’ interven-
tions were not acted on (around 12% of cases) GPs took addi-
tional or alternative actions to those recommended by the
pharmacists. This suggests that, by highlighting potential
problems with patients’ medication, pharmacists stimulated
GPs to make changes to their management of these patients.
This effect was also seen in the nursing home study by
Zermansky et al. where GPs took additional or alternative
actions to those recommended by pharmacists in 5% of
cases.[20,21]
In the PINCER trial the number of interventions recom-
mended per case varied, with half of cases having only one
intervention. Where multiple recommendations were made
they could be of the form ‘I recommend action A, but if this
is not suitable/accepted, then please consider action B’. This
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would be recorded as two separate interventions but it
would not be possible for a GP to accept both interventions.
This may in part explain why only one-third of pharmacists’
interventions were accepted in outcome measure 2; phar-
macists recommended two or more interventions in 45% of
the cases where they made recommendations. However it is
not possible to state with certainty that all of these recom-
mendations were mutually exclusive. Future studies of phar-
macists’ interventions should assess the form in which
recommendations are made when calculating levels of
acceptance.
PINCER trial pharmacists’ interventions were targeted to
the outcome measure being addressed. These interventions
were broadly applicable across the outcome measures in the
three groups, however: contraindicated prescribing, inad-
equate monitoring and dosing problems. This suggests that
these interventions could be broadly applicable to a wider
range of clinical situations related to these groups of outcome
measures. Many of these interventions were not predicted
before the start of the study. Instead, they developed from
pharmacists’ experience of working with the GPs and learn-
ing from each other. This highlights the importance of pro-
viding a forum where pharmacists can learn from each other
when engaging in new roles. This forum was created in the
PINCER trial through monthly group meetings between the
pharmacists and the trial manager.
As might be predicted from the broad range of different
recommendations made, the time spent resolving problems
in each case varied widely (from 0 to 180 min). However,
pharmacists reported spending a median of 20 min on each
case. This included the time needed to assess each case, make
recommendations and implement any agreed changes. This is
consistent with the average time taken to conduct medication
reviews in a previous study in primary care,[19] but is likely to
be lower in terms of overall time spent because there was little
face-to-face contact between patients and pharmacists in the
PINCER trial. Instead, medication reviews were largely
restricted to medical records because this was how the prac-
tices preferred to work (instead, GPs had face-to-face meet-
ings with patients).
The median time pharmacists spent on each case varied
depending on the outcome measure and practice list size.
Although outcome measure 2 (b-blockers in asthma) had the
lowest percentage of completed actions it was the most time-
consuming of the outcome measures. Before the study began
we predicted that outcome measure 2 would be the most dif-
ficult for pharmacists to address because of the complexity
of assessing the cases and lack of clear guidelines on how
to manage patients. This is reflected in the time taken to
review the cases and percentage of cases where actions were
completed.
Pharmacists required less time to review cases and recom-
mend interventions than anticipated at the start of the trial.
This suggests that, with adequate training, it may be possible
to ‘roll out’ the pharmacist intervention using existing phar-
macist staff within general practices.
Conclusions
Analysis of pharmacist-recorded data from the PINCER
trial suggests that the outcome measures usefully targeted
pharmacists’ activities towards patients who may have
been at risk of hazardous medicines management and that
GPs were largely supportive of the approach taken in the
trial.
This analysis has also highlighted areas which were
challenging for pharmacists to influence, such as the pre-
scription of b-blockers to patients with asthma and cardio-
vascular disease. The analysis has also identified some useful
interventions which could be applied to a wide range of
clinical scenarios. In addition, it would seem that the activi-
ties undertaken by the pharmacists were largely appropriate
to their level of training, although it may be possible
to identify some activities that could be undertaken
by less qualified staff, such as pharmacy technicians, once
pharmacists have performed a clinical review of individual
cases.
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